Kiromic BioPharma (KRBP) Welcomes Two New Directors to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023 3:00 PM EDTClinical and Regulatory Affairs Expert Pamela Misajon Brings Drug-Development Expertise
Finance and Technology Executive Michael Catlin to Chair the Audit Committee
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (NASDAQ: KRBP) (Kiromic or the Company), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors. Their regulatory and finance experience enhances Kiromics governance and re-establishes the Companys... More
